Because of the clinical success of LOR, US-FDA on 3 March 2021, has been approved LOR for patients with metastatic NSCLC whose tumors are ALK-positive, distinguished by an FDA-approved test [14]. This evidence concerns the gene ALK and non-small cell lung carcinoma.